TwinBeech Capital’s Filana Therapeutics FLNA Stock Holding History

TwinBeech Capital’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-20,588	Closed	-$505K	–	863
2023 Q2	$505K	Sell	20,588 -57,423	-74%	-$1.38M	0.01%	509
2023 Q1	$1.88M	Buy	78,011 +60,051	+334%	+$1.66M	0.04%	381
2022 Q4	$531K	Buy	+17,960	New	+$645K	0.01%	586

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

GCM

Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

TwinBeech Capital's FLNA Position: Q3 2023 in Review

TwinBeech Capital sold out of Filana Therapeutics (FLNA) in Q3 2023, closing a stake of 20,588 shares — an estimated $505K sold.

TwinBeech Capital first reported a position in FLNA in Q4 2022 and held it in 3 quarters. The position peaked at $1.88M in Q1 2023. 140 funds tracked by Wall St. Rank hold FLNA as of Q3 2023.

TwinBeech Capital reported no remaining Filana Therapeutics position as of Q3 2023 after selling out during the quarter.
TwinBeech Capital sold 20,588 Filana Therapeutics shares in Q3 2023, an estimated $505K.
TwinBeech Capital first reported a position in Filana Therapeutics in Q4 2022 and held it in 3 quarters.
TwinBeech Capital's Filana Therapeutics position peaked at $1.88M in Q1 2023.
140 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2023.

Based on TwinBeech Capital's 13F filing for Q3 2023, filed 14 Nov 2023.